S.A. Mason’s Ginkgo Bioworks DNA Stock Holding History

S.A. Mason’s Portfolio DNA Stock Details DNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-150	Closed	-$2.01K	–	325
2024 Q2	$2.01K	Hold	150	–	–	﹤0.01%	314
2024 Q1	$6.96K	Hold	150	–	–	﹤0.01%	299
2023 Q4	$10.1K	Hold	150	–	–	0.01%	294
2023 Q3	$10.9K	Hold	150	–	–	0.01%	290
2023 Q2	$7.98K	Hold	150	–	–	0.01%	297
2023 Q1	$7.98K	Hold	150	–	–	0.01%	297
2022 Q4	$10.1K	Hold	150	–	–	0.01%	294
2022 Q3	$19K	Buy	+150	New	+$17.9K	0.02%	290

Other funds holding DNA

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ACG

Anchorage Capital Group New York $450M AUM 41.75% 1-Year Est. Return

Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

S.A. Mason's DNA Position: Q3 2024 in Review

S.A. Mason sold out of Ginkgo Bioworks (DNA) in Q3 2024, closing a stake of 150 shares — an estimated $2.01K sold.

S.A. Mason first reported a position in DNA in Q3 2022 and held it in 8 quarters. The position peaked at $19K in Q3 2022. 159 funds tracked by Wall St. Rank hold DNA as of Q3 2024.

S.A. Mason reported no remaining Ginkgo Bioworks position as of Q3 2024 after selling out during the quarter.
S.A. Mason sold 150 Ginkgo Bioworks shares in Q3 2024, an estimated $2.01K.
S.A. Mason first reported a position in Ginkgo Bioworks in Q3 2022 and held it in 8 quarters.
S.A. Mason's Ginkgo Bioworks position peaked at $19K in Q3 2022.
159 funds tracked by Wall St. Rank held Ginkgo Bioworks as of Q3 2024.

Based on S.A. Mason's 13F filing for Q3 2024, filed 25 Oct 2024.